Original English content reproduced with permission. Source claims have not been independently validated by Peps MN. Peptide DB ↗
Teriparatide (PTH 1-34)
FDA ApprovedPTH(1-34) | Bone-Building Anabolic Peptide
20mcg daily (FDA-approved dose)
Once daily at same time each day
Maximum 2 years lifetime treatment
Pen: 2-8°C refrigerated, do not freeze. Discard after 28 days
Original Peptide DB content reproduced with permission. Source claims have not been independently validated by Peps MN. Source ↗
Teriparatide is an FDA-approved anabolic bone-building agent consisting of the first 34 amino acids of parathyroid hormone. Unlike antiresorptive osteoporosis drugs that slow bone loss, teriparatide actively stimulates new bone formation. The key to its mechanism is intermittent exposure: while continuous PTH causes bone resorption, daily injections stimulate osteoblasts more than osteoclasts, resulting in net bone formation. Clinical trials show 8% spine bone density increases and 65% reduction in vertebral fractures.
Teriparatide binds to PTH type 1 receptors (G-protein coupled receptors) on osteoblasts, osteocytes, and renal tubular cells. This activates PKA and PKC signaling pathways that promote osteoblast activity. The intermittent daily dosing creates an 'anabolic window' where bone formation exceeds resorption. Teriparatide upregulates IGF-1 and FGF2 expression, stimulates bone formation on trabecular and cortical surfaces, and increases bone mineral density through preferential osteoblast stimulation.
Molecular Data
N-terminal 1-34 of parathyroid hormone Complex or non-standard sequence format
Accumulation Curve
Example inputs are illustrative, not a dosing protocol.
Research Indications
FDA-approved for women with osteoporosis at high risk of fracture.
FDA-approved for men with primary or hypogonadal osteoporosis at high risk.
FDA-approved for men and women with osteoporosis from sustained corticosteroid use.
Research interest in accelerating fracture healing and bone repair.
Investigated for jawbone regeneration in dental applications.
Dosing Protocols
Teriparatide is administered as a once-daily subcutaneous injection, typically in the thigh or abdomen. It comes in pre-filled pen devices (Forteo) containing a 28-day supply. Treatment is typically limited to 2 years due to theoretical bone cancer risk from long-term use (seen only in rats at high doses).
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Osteoporosis treatment | 20 mcg | Once daily | SubQ (thigh or abdomen) |
Reconstitution Instructions
- Pre-filled pen device (Forteo)
- Pen needles
- Alcohol swabs
- 1 Store pen refrigerated (do not freeze)
- 2 Allow to reach room temperature before injection
- 3 Attach new needle for each injection
- 4 Inject subcutaneously in thigh or abdomen
- 5 Discard pen after 28 days even if medication remains
Interactions
What to Expect
Side Effects & Safety
Common Side Effects
- Injection site reactions
- Nausea
- Headache
- Leg cramps
- Dizziness
- Joint pain
Stop Signs - Discontinue if:
- Signs of hypercalcemia (confusion, fatigue, nausea)
- Persistent bone pain
- Allergic reactions
Contraindications
- Paget's disease of bone
- Prior skeletal radiation therapy
- History of skeletal malignancies
- Metabolic bone diseases other than osteoporosis
- Pre-existing hypercalcemia
- Pregnancy
Quality Checklist
Good Signs
- Clear, colorless solution
- Pharmaceutical grade (Forteo)
- Proper cold chain maintained
- Intact pen device
Warning Signs
- Research-grade products lack FDA oversight
- Temperature excursions may affect potency
Bad Signs
- Cloudy or discolored solution
- Particulates visible
- Exposed to freezing or high temperatures
Frequently Asked Questions
Why is teriparatide limited to 2 years when it builds bone so effectively?
Teriparatide is limited to 2 years due to a theoretical osteosarcoma risk observed in rat studies at very high doses over extended periods. Human clinical trials haven't shown this risk, but the FDA maintains the 2-year lifetime limit as a precautionary measure. After 2 years, antiresorptive therapy maintains the bone gains.
Can teriparatide reverse osteoporosis or just slow bone loss?
Teriparatide actively reverses osteoporosis by building new bone, unlike antiresorptive drugs that only slow loss. Clinical trials show 5-9% spine bone density increases and 65% fracture risk reduction - making it uniquely anabolic rather than protective.
Should teriparatide be taken with calcium and vitamin D?
Yes, adequate calcium and vitamin D intake are essential during teriparatide therapy. The peptide stimulates bone formation, which requires sufficient mineral substrate. Deficient calcium/vitamin D can blunt teriparatide's effects and potentially impair bone quality despite density gains.
How does teriparatide create an 'anabolic window' for bone formation?
Daily intermittent PTH exposure stimulates osteoblasts (bone-forming cells) more strongly than osteoclasts (bone-removing cells), creating a window where formation exceeds resorption. This contrasts with continuous PTH, which causes net bone loss. The daily injection timing is critical to maintain this anabolic advantage.
References
- TeriparatideStatPearls (NCBI Bookshelf) (2024)
Intermittent PTH exposure induces bone formation more than resorption; FDA-approved for osteoporosis.
- The effect of teriparatide therapy on bone density in men with osteoporosisPubMed (2002)
Spine BMD increased 5.9% (20mcg) and 9.0% (40mcg); femoral neck increased 1.5-2.9%.
- Teriparatide: 2.5 Years of ExperienceJournal of Bone and Mineral Research (2006)
Reduced vertebral fractures by 65% and nonvertebral fractures by 35% after 20 months.
- Parathyroid Hormone (1-84) and Teriparatide in Postmenopausal OsteoporosisWomen's Health (2006)
Initial formation without resorption creates 'anabolic window' for rapid bone volume increase.
Related Peptides
Disclaimer
This information is for educational and research purposes only. Consult a healthcare professional before use.
For education and research information only. Not individualized medical advice.